Cargando…

Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir

Integration of HIV DNA into host chromosome requires a 3′-processing (3′-P) and a strand transfer (ST) reactions catalyzed by virus integrase (IN). Raltegravir (RAL), commonly used in AIDS therapy, belongs to the family of IN ST inhibitors (INSTIs) acting on IN-viral DNA complexes (intasomes). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ammar, Farah F., Abdel-Azeim, Safwat, Zargarian, Loussinée, Hobaika, Zeina, Maroun, Richard G., Fermandjian, Serge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388078/ https://www.ncbi.nlm.nih.gov/pubmed/22768342 http://dx.doi.org/10.1371/journal.pone.0040223

Ejemplares similares

A targeted DNA substrate mechanism for the inhibition of HIV‐1 integrase by inhibitors with antiretroviral activity
por: Ammar, Farah F., et al.
Publicado: (2016)

Monoclonal antibodies that recognize important functional elements of the HIV-1 integrase enzyme
por: Maroun, Richard G, et al.
Publicado: (2012)

Specificity of LTR DNA recognition by a peptide mimicking the HIV-1 integrase α4 helix
por: Hobaika, Zeina, et al.
Publicado: (2009)

An Unusual Helix Turn Helix Motif in the Catalytic Core of HIV-1 Integrase Binds Viral DNA and LEDGF
por: Merad, Hayate, et al.
Publicado: (2009)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

Pre-organized structure of viral DNA at the binding-processing site of HIV-1 integrase
por: Renisio, Jean-Guillaume, et al.
Publicado: (2005)

The HIV-1 Integrase α4-Helix Involved in LTR-DNA Recognition Is also a Highly Antigenic Peptide Element
por: Azzi, Sandy, et al.
Publicado: (2010)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
por: Fernández-Caballero, Jose Ángel, et al.
Publicado: (2016)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
por: Machado, Lucas de Almeida, et al.
Publicado: (2019)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Quantum-Chemistry Based Design of Halobenzene Derivatives With Augmented Affinities for the HIV-1 Viral G(4)/C(16) Base-Pair
por: El Darazi, Perla, et al.
Publicado: (2020)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
por: Reigadas, Sandrine, et al.
Publicado: (2010)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Structural and functional characterizations reveal the importance of a zinc binding domain in Bloom's syndrome helicase
por: Guo, Rong-bin, et al.
Publicado: (2005)

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
por: Hulgan, Todd, et al.
Publicado: (2014)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

HIV-1 integrase SUMOylation and viral replication
por: Zamborlini, Alessia, et al.
Publicado: (2011)

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
por: Delelis, Olivier, et al.
Publicado: (2009)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
por: Orta-Resendiz, Aurelio, et al.
Publicado: (2020)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
por: Noguera-Julian, Marc, et al.
Publicado: (2013)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
por: Ni, Xiao-Ju, et al.
Publicado: (2011)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Higher order structural effects stabilizing the reverse Watson–Crick Guanine-Cytosine base pair in functional RNAs
por: Chawla, Mohit, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nl3v3sgb27jqmg0bgem8tqap88